BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Arterial Remodeling Technologies Reports that its Second-Generation Bioresorbable Stent Promotes Vessel Lumen Enlargement in Post-Angioplasty in Vivo Model


11/2/2011 10:37:11 AM

PARIS, Nov. 2, 2011—Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its second-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at three months follow-up. In addition, acute safety data are excellent: there have been more than 250 MACE-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.

The Company also reported that it has appointed interventional cardiologist Jean Fajadet, M.D., to its scientific advisory board. Dr. Fajadet is Co-Director of Interventional Cardiology at Clinique Pasteur, Toulouse, France; and, President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

“We are extremely pleased to have Dr. Fajadet, a key international opinion leader in interventional cardiology, join ART’s scientific advisory board,” said Machiel van der Leest, CEO. “Dr. Fajadet will play a critical role as we move toward our First-in-Human milestone with our second-generation bioresorbable stent.”

ART’s bioresorbable stent is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months. According to van der Leest, who has developed and successfully introduced 15 Class III medical devices during his career, this three-month scaffolding period is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following the trauma generated by angioplasty, and to avoid recoil and constrictive remodeling. Extensive in vivo data demonstrate that ART’s polymer is designed to be safe while triggering only a minimal inflammatory response that is typical for biocompatible resorption processes.

“The key characteristics of ART’s second-generation bioresorbable stent are that it is made of non-aggressive material, has a programmed transitory presence, and—most important—facilitates natural remodeling” said Antoine LaFont, M.D., Ph.D., Professor of Medicine, Head Interventional Cardiology Department, Georges Pompidou Hospital (Paris); and, Past Chairman, Interventional Cardiology Working Group, European Society of Cardiology (ESC). Pr. LaFont is a co-founder of ART.

ART’s novel biopolymers have been developed in conjunction with one of the world’s leading authorities in bioresorbable polymers, Research Professor Michel Vert, Ph.D., who is Former Director of the Research Center for Artificial Biopolymers at France’s National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS). Pr. Vert is a co-founder of ART.

About Arterial Remodeling Technologies (“ART”)

Arterial Remodeling Technologies (“ART”) is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES